Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for DiaMedica Therapeutics, Inc. (DMAC : NSDQ)

• Company Description    DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $3.76 Daily Weekly Monthly 20 Day Moving Average: 301,985 shares Shares Outstanding: 42.88 (millions) Market Capitalization: $161.24 (millions) Beta: 1.17 52 Week High: $6.82 52 Week Low: $2.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.07% -13.05% 12 Week 7.12% -10.13% Year To Date -30.75% -35.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 301 CARLSON PARKWAY SUITE 210 - MINNEAPOLIS,MN 55305 USA ph: 763-496-5454 fax: 763-710-4456 skellen@diamedica.com http://www.diamedica.com

• General Corporate Information    Officers Rick Pauls - Chief Executive Officer; President and Director James Parsons - Chairman Scott Kellen - Chief Financial Officer and Secretary Michael Giuffre - Director Richard Kuntz - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 25253X207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 42.88 Most Recent Split Date: 11.00 (0.05:1) Beta: 1.17 Market Capitalization: $161.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.75 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -28.57% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -61.35 12/31/24 - -51.85 ROA 06/30/25 - - 03/31/25 - -55.53 12/31/24 - -47.68 Current Ratio 06/30/25 - - 03/31/25 - 8.02 12/31/24 - 8.28 Quick Ratio 06/30/25 - - 03/31/25 - 8.02 12/31/24 - 8.28 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.79 12/31/24 - 0.95 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.03 12/31/24 - 0.03

Powered by Zacks Investment Research ©